More on This Topic Understanding the Role of GIP in Managing Diabetes and Obesity (Press release, 09.11.2023) Clinical safety of a triple gut hormone co-agonist: The future of obesity therapy
" Page 170 and 171: Gleick PH, Cooley H, Cohen MJ, Mori Page 172 and 173: Gomez E, Fenet H, Pillon A, Rosain Page 174 and 175: Goossens H, Ferech M, Vander Stiche Page 176 and 177: Grange AH, Osemwengie LI, Brilis GM Page 178 and 179: France, Envirpharma, 14-16 April, 2 Page 180 and 181: Grote M, Vockel A, Schwarze D, Mehl Page 182 and 183: Guinea E, Arias C, Cabot PL, Garrid Page 184 and 185: Gupta V and Rahman SZ
Gentle enough for daily use even when everything else has failed
Quality statement 6: 9 key care processes | Type 2 diabetes in adults (QS209)
However, if you have recurrent kidney stones alongside other metabolic risk factors such as obesity, diabetes, or abnormal liver function tests, your GP may assess your overall metabolic health and arrange appropriate investigations
This means they have not been tested for safety, effectiveness, or quality control
